terazosin has been researched along with Hypotension in 7 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
Hypotension: Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to evaluate the safety and efficacy of the selective alpha 1-adrenoceptor blocker terazosin in the treatment of benign prostatic hyperplasia (BPH)." | 9.08 | A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. ( Barkin, J; Beland, G; Boake, RC; Casey, RW; Elhilali, MM; Fradet, Y; Klotz, LH; Orovan, WL; Ramsey, EW; Schick, E; Trachtenberg, J, 1996) |
| "To examine the clinical usefulness of selective and non-selective alpha 1-adrenoceptor antagonists, we compared a selective (tamsulosin) and non-selective (terazosin) alpha 1-adrenoceptor antagonists in the treatment of Chinese patients with benign prostatic hyperplasia (BPH)." | 9.08 | Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. ( Gu, FL; Guo, YL; Na, YJ, 1998) |
| "In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia." | 8.79 | Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. ( Lowe, FC; McKiernan, JM, 1997) |
| "This study was designed to evaluate the safety and efficacy of the selective alpha 1-adrenoceptor blocker terazosin in the treatment of benign prostatic hyperplasia (BPH)." | 5.08 | A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. ( Barkin, J; Beland, G; Boake, RC; Casey, RW; Elhilali, MM; Fradet, Y; Klotz, LH; Orovan, WL; Ramsey, EW; Schick, E; Trachtenberg, J, 1996) |
| "To examine the clinical usefulness of selective and non-selective alpha 1-adrenoceptor antagonists, we compared a selective (tamsulosin) and non-selective (terazosin) alpha 1-adrenoceptor antagonists in the treatment of Chinese patients with benign prostatic hyperplasia (BPH)." | 5.08 | Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. ( Gu, FL; Guo, YL; Na, YJ, 1998) |
| "In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia." | 4.79 | Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. ( Lowe, FC; McKiernan, JM, 1997) |
| "Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation." | 3.71 | Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001) |
| " These compounds, when dosed of 1." | 1.42 | α-Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one. ( Bednarski, M; Dudek, M; Kulig, K; Lustyk, K; Malawska, B; Nowiński, L; Raźny, K; Sapa, J; Siwek, A; Starowicz, G; Zaręba, P, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zaręba, P | 1 |
| Dudek, M | 1 |
| Lustyk, K | 1 |
| Siwek, A | 1 |
| Starowicz, G | 1 |
| Bednarski, M | 1 |
| Nowiński, L | 1 |
| Raźny, K | 1 |
| Sapa, J | 1 |
| Malawska, B | 1 |
| Kulig, K | 1 |
| Belayneh, M | 1 |
| Korownyk, C | 1 |
| Elhilali, MM | 1 |
| Ramsey, EW | 1 |
| Barkin, J | 1 |
| Casey, RW | 1 |
| Boake, RC | 1 |
| Beland, G | 1 |
| Fradet, Y | 1 |
| Trachtenberg, J | 1 |
| Orovan, WL | 1 |
| Schick, E | 1 |
| Klotz, LH | 1 |
| McKiernan, JM | 1 |
| Lowe, FC | 1 |
| Na, YJ | 1 |
| Guo, YL | 1 |
| Gu, FL | 1 |
| Chrischilles, E | 1 |
| Rubenstein, L | 1 |
| Chao, J | 1 |
| Kreder, KJ | 1 |
| Gilden, D | 1 |
| Shah, H | 1 |
| Feldman, T | 1 |
| Carroll, JD | 1 |
| Munkenbeck, F | 1 |
| Alibali, P | 1 |
| Feldman, M | 1 |
| Coggins, DL | 1 |
| Gray, KR | 1 |
| Bump, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for terazosin and Hypotension
| Article | Year |
|---|---|
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
Topics: Adrenergic alpha-Antagonists; Dizziness; Doxazosin; Humans; Hypotension; Lower Urinary Tract Symptom | 2016 |
Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Clinical Trials as Topic; Dizziness; Humans; | 1997 |
2 trials available for terazosin and Hypotension
| Article | Year |
|---|---|
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Canada; Double-Blind Me | 1996 |
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Dose-Response Relations | 1998 |
3 other studies available for terazosin and Hypotension
| Article | Year |
|---|---|
α-Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Dose-Response Relationship, Drug; Hypotension; Mal | 2015 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comor | 2001 |
Hemodynamic recovery during simulated ventricular tachycardia: role of adrenergic receptor activation.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cardiac Pacing, Artificial; Dise | 1988 |